Cancer Family
Embryonal Neoplasm
CI-CAN-00000013Explore in graph →
Non-malignant285 active trials7 approved drugs73 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000013Explore in graph →
Clinical trials
1,126 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06485947 | Study Combining Dinutuximab Beta With Two Chemotherapy Regimens in Neuroblastoma(DBPilot) | recruiting | Phase 1 | 38 | Princess Maxima Center for Pediatric OncologyOTHER | 1 | Jul 8, 2025 | clinicaltrials |
| NCT00703222 | A Phase I/II Study Of Immunization With Lymphotactin And Interleukin 2 Gene Modified Neuroblastoma Tumor Cells(CHESAT) | completed | Phase 1 / Phase 2 | 7 | Baylor College of MedicineOTHER | 1 |
| Jul 4, 2025 |
| clinicaltrials |
| NCT03037385 | Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors(ARROW) | completed | Phase 1 / Phase 2 | 590 | Hoffmann-La RocheINDUSTRY | 13 | May 31, 2025 | clinicaltrials |
| NCT04040231 | Using a Targeted Cancer Vaccine (Galinpepimut-S) With Immunotherapy (Nivolumab) in Mesothelioma | completed | Phase 1 | 10 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 13, 2025 | clinicaltrials |
| NCT06948994 | A Clinical Trial on Autologous NK Cells Combined With GD2 Monoclonal Antibody in the Treatment of Children With Newly Diagnosed High-risk or Relapsed/Refractory Neuroblastoma | not yet recruiting | Phase 1 / Phase 2 | 15 | Guangzhou Women and Children's Medical CenterOTHER | 0 | Apr 29, 2025 | clinicaltrials |
| NCT03332667 | MIBG With Dinutuximab +/- Vorinostat | completed | Phase 1 | 45 | New Approaches to Neuroblastoma Therapy ConsortiumOTHER | 1 | Apr 16, 2025 | clinicaltrials |
| NCT06674265 | Safety and Efficacy of Systemic Allogenic NK Cells in R/R Neuroblastoma | recruiting | Phase 1 | 10 | Marzieh EbrahimiINDUSTRY | 1 | Apr 9, 2025 | clinicaltrials |
| NCT00638898 | Busulfan, Melphalan, Topotecan Hydrochloride, and a Stem Cell Transplant in Treating Patients With Newly Diagnosed or Relapsed Solid Tumor | completed | Phase 1 | 25 | City of Hope Medical CenterOTHER | 1 | Mar 20, 2025 | clinicaltrials |
| NCT04239040 | GVAX Plus Checkpoint Blockade in Neuroblastoma | terminated | Phase 1 | 19 | Dana-Farber Cancer InstituteOTHER | 1 | Mar 19, 2025 | clinicaltrials |
| NCT04246671 | TAEK-VAC-HerBy Vaccine for Brachyury and HER2 Expressing Cancer | completed | Phase 1 | 37 | Bavarian NordicINDUSTRY | 1 | Mar 3, 2025 | clinicaltrials |
| NCT06836505 | Safety and Efficacy of CAR-T Cell Therapy for Relapsed/refractory Neuroblastoma and Desmoplastic Small Round Cell Tumors: a Single-arm, Open-label Trial. | recruiting | Phase 1 / Phase 2 | 10 | Sun Yat-Sen University Cancer CenterOTHER | 1 | Feb 26, 2025 | clinicaltrials |
| NCT03647423 | QUILT-3.091 NANT Chordoma Vaccine vs Radiation in Subjects With Unresectable Chordoma. | withdrawn | Phase 1 / Phase 2 | 0 | ImmunityBio, Inc.INDUSTRY | 1 | Feb 21, 2025 | clinicaltrials |
| NCT06631391 | Phase I Study of Umbilical Cord Blood Natural Killer (NK) Cell Therapy for Children With High-risk, R/R Neuroblastoma. | recruiting | Phase 1 | 30 | Sun Yat-sen UniversityOTHER | 1 | Feb 20, 2025 | clinicaltrials |
| NCT04537715 | Effects of Itraconazole and Rifampin on the Blood Tazemetostat Levels | completed | Phase 1 | 42 | Epizyme, Inc.INDUSTRY | 2 | Feb 19, 2025 | clinicaltrials |
| NCT02030964 | N2012-01: Phase 1 Study of Difluoromethylornithine (DFMO) and Celecoxib With Cyclophosphamide/Topotecan(DFMO) | completed | Phase 1 | 30 | New Approaches to Neuroblastoma Therapy ConsortiumOTHER | 3 | Feb 17, 2025 | clinicaltrials |
| NCT03190174 | Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma and Certain Cancers | completed | Phase 1 / Phase 2 | 34 | Sarcoma Oncology Research Center, LLCOTHER | 1 | Feb 17, 2025 | clinicaltrials |
| NCT02657005 | TK216 in Patients With Relapsed or Refractory Ewing Sarcoma | terminated | Phase 1 / Phase 2 | 85 | Oncternal Therapeutics, IncINDUSTRY | 1 | Feb 12, 2025 | clinicaltrials |
| NCT01868490 | The Adoptive Immunotherapy for Solid Tumors Using Modified Autologous CIK Cells | enrolling by invitation | Phase 1 / Phase 2 | 20 | Siriraj HospitalOTHER | 1 | Feb 10, 2025 | clinicaltrials |
| NCT04023669 | Evaluation of LY2606368 Therapy in Combination With Cyclophosphamide or Gemcitabine for Children and Adolescents With Refractory or Recurrent Group 3/Group 4 or SHH Medulloblastoma Brain Tumors | completed | Phase 1 | 21 | St. Jude Children's Research HospitalOTHER | 1 | Feb 7, 2025 | clinicaltrials |
| NCT06751134 | Chimeric Natural Killer Receptor-Universal T Cells for Relapsed or Refractory Neuroblastoma | recruiting | Phase 1 | 12 | Nanjing Children's HospitalOTHER | 1 | Feb 7, 2025 | clinicaltrials |
| NCT02076906 | MR-guided High Intensity Focused Ultrasound (HIFU) on Pediatric Solid Tumors | completed | Phase 1 | 7 | AeRang KimOTHER | 1 | Jan 1, 2025 | clinicaltrials |
| NCT04758533 | Clinical Trial to Assess the Safety and Efficacy of AloCELYVIR With Newly Diagnosed Diffuse Intrinsic Pontine Glioma (DIPG) in Combination With Radiotherapy or Medulloblastoma in Monotherapy(AloCELYVIR) | active not recruiting | Phase 1 / Phase 2 | 13 | Hospital Infantil Universitario Niño Jesús, Madrid, SpainOTHER | 1 | Dec 27, 2024 | clinicaltrials |
| NCT00002730 | Chemotherapy in Treating Children With Neuroblastoma | completed | Phase 1 | — | New Approaches to Neuroblastoma Therapy ConsortiumOTHER | 1 | Nov 20, 2024 | clinicaltrials |
| NCT04521946 | Chemotherapy and Donor Stem Transplant for the Treatment of Patients With High Grade Brain Cancer | withdrawn | Phase 1 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Oct 26, 2024 | clinicaltrials |
| NCT03990597 | StrataXRT in Preventing Radiation Dermatitis in Pediatric Patients Undergoing Radiation Therapy to the Brain or Spinal Cord | withdrawn | Phase 1 | 0 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 9, 2024 | clinicaltrials |
| NCT02601937 | EZH2 Inhibitor Tazemetostat in Pediatric Subjects With Relapsed or Refractory INI1-Negative Tumors or Synovial Sarcoma | completed | Phase 1 | 109 | Epizyme, Inc.INDUSTRY | 9 | Oct 3, 2024 | clinicaltrials |
| NCT03604783 | Phase 1, First-in-human Study of Oral TP-1287 in Patients with Advanced Solid Tumors | terminated | Phase 1 | 74 | Sumitomo Pharma America, Inc.INDUSTRY | 1 | Sep 19, 2024 | clinicaltrials |
| NCT00867568 | TPI 287 in Patients With Refractory or Recurrent Neuroblastoma or Medulloblastoma | completed | Phase 1 | 18 | Giselle ShollerOTHER | 1 | Aug 6, 2024 | clinicaltrials |
| NCT01059071 | Safety Study for Refractory or Relapsed Neuroblastoma With DFMO Alone and in Combination With Etoposide | completed | Phase 1 | 21 | Giselle ShollerOTHER | 1 | Aug 6, 2024 | clinicaltrials |
| NCT01483820 | Safety and Efficacy Study of TPI-287 in Neuroblastoma and Medulloblastoma | terminated | Phase 1 / Phase 2 | 8 | Giselle ShollerOTHER | 1 | Aug 6, 2024 | clinicaltrials |
| NCT01505608 | Randomized Efficacy Study of TPI 287 to Treat Primary Refractory or Early Relapsed Neuroblastoma | terminated | Phase 1 / Phase 2 | 14 | Giselle ShollerOTHER | 1 | Aug 6, 2024 | clinicaltrials |
| NCT02630043 | Trial of Tolcapone With Oxaliplatin for Neuroblastoma | terminated | Phase 1 | 5 | Giselle ShollerOTHER | 1 | Aug 6, 2024 | clinicaltrials |
| NCT01798004 | Busulfan, Melphalan, and Stem Cell Transplant After Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma | completed | Phase 1 | 150 | Children's Oncology GroupNETWORK | 4 | Jul 15, 2024 | clinicaltrials |
| NCT02110563 | Phase I, Multicenter, Dose Escalation Study of DCR-MYC in Patients With Solid Tumors, Multiple Myeloma, or Lymphoma | terminated | Phase 1 | 50 | Dicerna Pharmaceuticals, Inc., a Novo Nordisk companyINDUSTRY | 1 | Jul 11, 2024 | clinicaltrials |
| NCT06485908 | Axitinib and Oral Metronomic Etoposide for Pediatric Children and AYA Refractory/Relapsing Medulloblastoma and Ependymoma(MEPENDAX) | not yet recruiting | Phase 1 / Phase 2 | 40 | Assistance Publique Hopitaux De MarseilleOTHER | 0 | Jul 3, 2024 | clinicaltrials |
| NCT05093322 | A Study of Surufatinib in Combination With Gemcitabine in Pediatric, Adolescent, and Young Adult Patients With Recurrent or Refractory Solid Tumors | completed | Phase 1 / Phase 2 | 13 | HutchmedINDUSTRY | 1 | Jun 7, 2024 | clinicaltrials |
| NCT03434262 | SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors | completed | Phase 1 | 68 | St. Jude Children's Research HospitalOTHER | 1 | May 31, 2024 | clinicaltrials |
| NCT02107963 | A Phase I Trial of T Cells Expressing an Anti-GD2 Chimeric Antigen Receptor in Children and Young Adults With GD2+ Solid Tumors | completed | Phase 1 | 15 | National Cancer Institute (NCI)NIH | 1 | May 16, 2024 | clinicaltrials |
| NCT03043391 | Phase 1b Study PVSRIPO for Recurrent Malignant Glioma in Children | completed | Phase 1 | 8 | Istari Oncology, Inc.INDUSTRY | 1 | Apr 8, 2024 | clinicaltrials |
| NCT06340204 | Weekly Irinotecan Liposomes in Recurrent or Refractory Ewing Sarcoma | recruiting | Phase 1 | 44 | Peking University People's HospitalOTHER | 1 | Apr 3, 2024 | clinicaltrials |
| NCT05952687 | Trial of Idasanutlin and Selinexor Therapy for Children With Progressive/Relapsed AT/RT or Extra-CNS Malignant Rhabdoid Tumors | withdrawn | Phase 1 | 0 | St. Jude Children's Research HospitalOTHER | 0 | Mar 27, 2024 | clinicaltrials |
| NCT02962167 | Modified Measles Virus (MV-NIS) for Children and Young Adults With Recurrent Medulloblastoma or Recurrent ATRT | completed | Phase 1 | 34 | Sabine Mueller, MD, PhDOTHER | 1 | Mar 20, 2024 | clinicaltrials |
| NCT01386619 | NK DLI in Patients After Human Leukocyte Antigen (HLA)-Haploidentical Hematopoietic Stem Cell Transplantation (HSCT) | completed | Phase 1 / Phase 2 | 15 | University Hospital, Basel, SwitzerlandOTHER | 2 | Mar 19, 2024 | clinicaltrials |
| NCT02765243 | Anti-GD2 4th Generation CART Cells Targeting Refractory and/or Recurrent Neuroblastoma(4SCAR-GD2) | completed | Phase 1 | 12 | Zhujiang HospitalOTHER | 1 | Mar 15, 2024 | clinicaltrials |
| NCT01661400 | Anti-Angiogenic Therapy Post Transplant (ASCR) for Pediatric Solid Tumors(ASCR) | completed | Phase 1 | 14 | Washington University School of MedicineOTHER | 1 | Jan 31, 2024 | clinicaltrials |
| NCT02457845 | HSV G207 Alone or With a Single Radiation Dose in Children With Progressive or Recurrent Supratentorial Brain Tumors | completed | Phase 1 | 13 | Gregory K. Friedman, MDOTHER | 1 | Jan 19, 2024 | clinicaltrials |
| NCT01606878 | Crizotinib and Combination Chemotherapy in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma | completed | Phase 1 | 46 | Children's Oncology GroupNETWORK | 2 | Jan 5, 2024 | clinicaltrials |
| NCT00089245 | Radiolabeled MAB Therapy in Patients With Refractory, Recurrent, or Advanced CNS or Leptomeningeal Cancer | terminated | Phase 1 | 177 | Y-mAbs TherapeuticsINDUSTRY | 1 | Dec 26, 2023 | clinicaltrials |
| NCT03458728 | Safety, Tolerability, Efficacy and Pharmacokinetics of Copanlisib in Pediatric Patients | terminated | Phase 1 / Phase 2 | 31 | BayerINDUSTRY | 1 | Dec 4, 2023 | clinicaltrials |
Data updated 23 days agoSource updated Jul 8, 2025source: clinicaltrials